Abstract
Hepatitis C virus (HCV) infections are a serious viral health problem globally, causing liver cirrhosis and inflammation that can develop to hepatocellular carcinoma and death. Since the HCV NS3/4A protease complex cleaves the scissile peptide bond in the viral encoded polypeptide to release the non-structural proteins during the viral replication process, this protease is then an important target for drug design. The computer-aided drug design and screening targeted at NS3/4A protease of HCV were reviewed. In addition, using steered molecular dynamics simulations, potent inhibitors of the NS3/4A complex were searched for by screening the ZINC database based upon the hypothesis that a high rupture force indicates a high binding efficiency. Nine top-hit compounds (59500093, 59784724, 13527817, 26660256, 29482733, 25977181, 28005928, 13527826 and 13527826) were found that had the same or a greater maximum rupture force (and so assumed binding strength and inhibitory potency) than the four current drugs and so are potential candidates as anti- HCV chemotherapeutic agents. In addition, van der Waals interactions were found to be the main contribution in stabilizing the ligand- NS3/4A complex.
Keywords: NS3/4A protease, hepatitis C virus, steered molecular dynamics simulations.
Current Pharmaceutical Design
Title:In Silico Screening for Potent Inhibitors against the NS3/4A Protease of Hepatitis C Virus
Volume: 20 Issue: 21
Author(s): Arthitaya Meeprasert, Thanyada Rungrotmongkol, Mai Suan Li and Supot Hannongbua
Affiliation:
Keywords: NS3/4A protease, hepatitis C virus, steered molecular dynamics simulations.
Abstract: Hepatitis C virus (HCV) infections are a serious viral health problem globally, causing liver cirrhosis and inflammation that can develop to hepatocellular carcinoma and death. Since the HCV NS3/4A protease complex cleaves the scissile peptide bond in the viral encoded polypeptide to release the non-structural proteins during the viral replication process, this protease is then an important target for drug design. The computer-aided drug design and screening targeted at NS3/4A protease of HCV were reviewed. In addition, using steered molecular dynamics simulations, potent inhibitors of the NS3/4A complex were searched for by screening the ZINC database based upon the hypothesis that a high rupture force indicates a high binding efficiency. Nine top-hit compounds (59500093, 59784724, 13527817, 26660256, 29482733, 25977181, 28005928, 13527826 and 13527826) were found that had the same or a greater maximum rupture force (and so assumed binding strength and inhibitory potency) than the four current drugs and so are potential candidates as anti- HCV chemotherapeutic agents. In addition, van der Waals interactions were found to be the main contribution in stabilizing the ligand- NS3/4A complex.
Export Options
About this article
Cite this article as:
Meeprasert Arthitaya, Rungrotmongkol Thanyada, Li Suan Mai and Hannongbua Supot, In Silico Screening for Potent Inhibitors against the NS3/4A Protease of Hepatitis C Virus, Current Pharmaceutical Design 2014; 20 (21) . https://dx.doi.org/10.2174/13816128113199990632
DOI https://dx.doi.org/10.2174/13816128113199990632 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Enhancing the Delivery of Anti Retroviral Drug “Saquinavir” Across the Blood Brain Barrier Using Nanoparticles
Current HIV Research Perspectives of Medieval Persian Medicine on Multiple Sclerosis
Current Drug Metabolism Modulation of γ<sub>2</sub>-MSH Hepatoprotection by Antisense Peptides and Melanocortin Subtype 3 and 4 Receptor Antagonists
Medicinal Chemistry Antifungal Therapy Used in Central Nervous System Fungal Infections
Central Nervous System Agents in Medicinal Chemistry Involvement of Toll-like Receptors in Ischemia-induced Neuronal Damage
Central Nervous System Agents in Medicinal Chemistry Antiviral Treatment of Cytomegalovirus Infection
Infectious Disorders - Drug Targets <i>In Silico</i> Analysis of Drug Repurposing Strategy for the Identification of Potential NS3 Helicase Inhibitors Against Zika Virus
Current Chinese Science Immunotherapy for Alzheimers Disease: Rational Basis in Ongoing Clinical Trials
Current Pharmaceutical Design Evaluating a Child with Partial Developmental Delay (ParDD), Global Developmental Delay (GDD)/Mental Retardation (MR): Clinical Expertise Based or Evidence-Based?
Current Pediatric Reviews Vitamin D: A Pleiotropic Hormone with Possible Psychotropic Activities
Current Medicinal Chemistry Mathematical Models for the Management of Helminth Parasites: From Biological Processes to the Evolution of Anthelmintic Resistance
Anti-Infective Agents in Medicinal Chemistry Electroporation Advances in Large Animals
Current Gene Therapy Isolation of Antibodies From Non-Human Primates for Clinical Use
Current Drug Discovery Technologies The Use of the Inhibitory Receptors for Modulating the Immune Responses
Current Pharmaceutical Design Microglial Activation and its Implications in the Brain Diseases
Current Medicinal Chemistry Intracellular Protozoan Parasites of Humans: The Role of Molecular Chaperones in Development and Pathogenesis
Protein & Peptide Letters Conformations and Assembly of Amyloid Oligomers by Electrospray Ionisation - Ion Mobility Spectrometry - Mass Spectrometry
Current Analytical Chemistry Substance Abuse, HIV-1 and Hepatitis
Current HIV Research A Comprehensive Review of Alzheimer’s Association with Related Proteins: Pathological Role and Therapeutic Significance
Current Neuropharmacology Alcohol Abuse and HIV Infection: Role of DRD2
Current HIV Research